| Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma M Vassilakopoulou, M Avgeris, V Velcheti, V Kotoula, T Rampias, ... Clinical Cancer Research 22 (3), 704-713, 2016 | 207 | 2016 |
| A new tumor suppressor role for the Notch pathway in bladder cancer T Rampias, P Vgenopoulou, M Avgeris, A Polyzos, K Stravodimos, ... Nature medicine 20 (10), 1199-1205, 2014 | 194 | 2014 |
| Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma A Strati, G Koutsodontis, G Papaxoinis, I Angelidis, M Zavridou, ... Annals of Oncology 28 (8), 1923-1933, 2017 | 189 | 2017 |
| The lysine‐specific methyltransferase KMT 2C/MLL 3 regulates DNA repair components in cancer T Rampias, D Karagiannis, M Avgeris, A Polyzos, A Kokkalis, Z Kanaki, ... EMBO reports 20 (3), e46821, 2019 | 122 | 2019 |
| SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions A Galani, R Aalizadeh, M Kostakis, A Markou, N Alygizakis, T Lytras, ... Science of The Total Environment 804, 150151, 2022 | 117 | 2022 |
| Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance M Avgeris, K Mavridis, A Scorilas Biological chemistry 393 (5), 301-317, 2012 | 113 | 2012 |
| The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients M Avgeris, K Stravodimos, EG Fragoulis, A Scorilas British journal of cancer 108 (12), 2573-2581, 2013 | 110 | 2013 |
| Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies M Avgeris, K Mavridis, A Scorilas Biological chemistry 391 (5), 505-511, 2010 | 107 | 2010 |
| Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives N Alygizakis, AN Markou, NI Rousis, A Galani, M Avgeris, ... TrAC Trends in Analytical Chemistry 134, 116125, 2021 | 101 | 2021 |
| Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment M Avgeris, K Mavridis, T Tokas, K Stravodimos, EG Fragoulis, A Scorilas Carcinogenesis 36 (5), 528-537, 2015 | 79 | 2015 |
| Revisiting histone deacetylases in human tumorigenesis: The paradigm of urothelial bladder cancer AF Giannopoulou, AD Velentzas, EG Konstantakou, M Avgeris, ... International journal of molecular sciences 20 (6), 1291, 2019 | 59 | 2019 |
| Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies M Avgeris, A Scorilas Expert opinion on therapeutic targets 20 (7), 801-818, 2016 | 54 | 2016 |
| Kallikrein‐related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance M Avgeris, K Stravodimos, A Scorilas The Prostate 71 (16), 1780-1789, 2011 | 49 | 2011 |
| Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer M Avgeris, G Koutalellis, EG Fragoulis, A Scorilas Clinical biochemistry 41 (14-15), 1140-1149, 2008 | 49 | 2008 |
| miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers K Panoutsopoulou, M Avgeris, A Scorilas Expert review of molecular diagnostics 18 (11), 963-979, 2018 | 48 | 2018 |
| miR-15a-5p, a novel prognostic biomarker, predicting recurrent colorectal adenocarcinoma CK Kontos, P Tsiakanikas, M Avgeris, IN Papadopoulos, A Scorilas Molecular Diagnosis & Therapy 21, 453-464, 2017 | 45 | 2017 |
| Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions M Avgeris, G Papachristopoulou, A Polychronis, A Scorilas Clinical proteomics 8, 1-12, 2011 | 42 | 2011 |
| Expression analysis and study of KLK4 in benign and malignant breast tumours G Papachristopoulou, M Avgeris, A Scorilas Thrombosis and haemostasis 101 (02), 381-387, 2009 | 42 | 2009 |
| Circulating miR‐146a and miR‐134 in predicting drug‐resistant epilepsy in patients with focal impaired awareness seizures M Leontariti, M Avgeris, MS Katsarou, N Drakoulis, A Siatouni, ... Epilepsia 61 (5), 959-970, 2020 | 41 | 2020 |
| Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients M Avgeris, A Tsilimantou, PK Levis, T Tokas, DC Sideris, K Stravodimos, ... British journal of cancer 119 (12), 1477-1486, 2018 | 41 | 2018 |
